LambdaTest Partners with LinkedIn to Offer Test Automation Professional Certificate on LinkedIn Learning
6.3.2023 19:00:00 EET | Business Wire | Press release
LambdaTest, the leading digital experience testing cloud platform, has partnered with LinkedIn to offer the LambdaTest Test Automation Professional Certificate exclusively available on LinkedIn Learning, as part of its mission to support the testing and QA community.
Through this Professional Certificate course, learners will acquire fundamental knowledge of test automation, including various tools and best practices, in a highly engaging manner from Meaghan Lewis, Technical Program Manager at Microsoft.
More importantly, learners will be able to implement and optimize test automation in their jobs after this course. To earn their LambdaTest Test Automation Professional Certificate, learners will have to complete all courses and content in the learning path and pass the final exam. Learners can access their certificates immediately after they pass the final exam and seamlessly showcase their certificate on LinkedIn.
"We are excited to partner with LambdaTest to provide our customers and learners additional, credible paths to upskilling as well as broaden the audience for the LambdaTest Test Automation Professional Certificate to the world’s largest talent marketplace," said Dan Brodnitz, Sr. Director of Global Content Strategy at LinkedIn Learning.
As LinkedIn Learning students for the LambdaTest Test Automation Professional Certificate, learners can get free trial access to the LambdaTest platform. This enables learners to get hands-on experience and implement the concepts.
“Enterprises, all over the world, are automating their testing to ensure a better digital experience for their users. Learning test automation will open up various career avenues for learners. We are also happy to offer free access to the LambdaTest platform to enable students to get hands-on experience. We are excited to play our role in enabling thousands of learners to achieve their career goals,” said Maneesh Sharma, Chief Operating Officer, LambdaTest.
LambdaTest recently announced the launch of digital experience testing cloud for enterprises. The offering will enable enterprises to accelerate their digital transformation by providing a best-in-class, 360-degree test execution and orchestration platform coupled with insightful test analytics and customizable deployment options.
Also, Satya Nadella, Chairman & CEO of Microsoft, delivered the keynote address at the Microsoft Future Ready Technology Summit 2023, Bengaluru, where he said that “LambdaTest is doing for test automation what Kubernetes did for container orchestration - creating that next level of efficiency around test automation so that people can actually focus on testing versus test orchestration.”
To know more, visit: https://www.lambdatest.com/certifications/linkedin-learning
Notes to the editor
For further information please contact the LambdaTest press office: press@lambdatest.com.
About LambdaTest
LambdaTest is a leading digital experience testing cloud that helps developers and testers ship code faster. Over 10,000+ enterprise customers and 2+ million users across 130+ countries rely on LambdaTest for their testing needs.
LambdaTest platform provides secure, scalable, and insightful test orchestration for customers at different points in their DevOps (CI/CD) lifecycle:
● Cross Browser Testing Cloud
LambdaTest test execution platform allows users to run both manual and automated tests across 3000+ different browsers, real devices, and operating system environments. It enables developers to test their websites, web applications, and native apps without requiring to install or maintain an internal lab of virtual machines, real devices, emulators, or simulators.
● Real Device Testing Cloud
With LambdaTest’s Real Devices Testing Cloud, you can now test unhandled errors, UI/UX, performance, and functionality of your native, web, and hybrid apps before they get released into production. Test on the widest range of mobile and OTT devices (iOS, Android, iPad, Amazon Fire TV, Roku TV & Apple TV). With seamless cross-functional team collaboration across the mobile app development lifecycle, you can release quality mobile apps in shorter development cycles which enables you to innovate and scale rapidly.
● Continuous Testing Cloud - HyperExecute
An IP-led next-gen cloud test execution and orchestration platform that helps enterprises run end-to-end automation tests at the fastest speed possible, thereby enabling them to achieve quicker time-to-market, and deliver a quality digital experience. Achieve 70% faster test execution times and zero flakiness with HyperExecute.
● Visual Regression cloud
Perform Regression Testing in just one click using LambdaTest. Compare the screenshots of your application’s webpages taken from two different browsers to view/detect any visual deviations. Increase browser coverage by running automation scripts on a cloud of 3000+ different desktop and mobile environments.
● Test Intelligence at Scale
Test execution insights are critical for digital transformation as they provide enterprises with more profound insight into the quality of releases and trends. By analyzing the test execution data, LambdaTest's Integrated Test Intelligence delivers enterprises with insights into patterns and trends that can lead to informed decisions about future development and improve application quality.
For more information, please visit: https://lambdatest.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230306005067/en/
Contact information
LambdaTest press office:
press@lambdatest.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom